Vidyya Medical News Service
Volume 6 Issue 143 Published - 14:00 UTC 08:00 EST 22-May-2004 Next Update - 14:00 UTC 08:00 EST 23-May-2004
little clear gif used for spacer

FDA approves new drug for bone marrow disease
The Food and Drug Administration (FDA) announced the approval of Vidaza (azacitidine) injection, the first effective treatment for patients with Myelodysplastic Syndrome (MDS). The product was given Fast Track Status and a priority review.  more

Prescribing information: Vidaza (azacitidine)
Vidaza is believed to exert its anticancer effects by causing demethylation, or hypomethylation, of DNA in abnormal blood-forming (hematopoietic) cells in the bone marrow as well as through its direct cytotoxic effect. Demethylation may restore normal function to tumor- suppressor genes which are responsible for regulating cell differentiation and growth. The cytotoxic effects of azacitidine cause the death of rapidly- dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non-proliferating cells are relatively insensitive to Vidaza.  more

FDA approves new indication for Taxotere: Prostate cancer
The Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.  more


Prescribing information: Taxotere (docetaxel)
Taxotere works by inhibiting tubulin, a protein essential to cell division, thus preventing cancer cells from dividing and growing in number. Get the full prescribing information, today in Vidyya.  more

New study raises questions about the number of people in the UK who could be incubating vCJD
A team of UK scientists found that 3 out of 12,674 stored appendix and tonsil samples showed evidence of the prion protein associated with vCJD, but urge caution about the way these results are interpreted. The research is published this week in The Journal of Pathology.  more

Center of reasoning and problem solving is among the brain's last to mature
The brain's center of reasoning and problem solving is among the last to mature, a new study graphically reveals. The decade-long magnetic resonance imaging (MRI) study of normal brain development, from ages 4 to 21, by researchers at NIH's National Institute of Mental Health (NIMH) and University of California Los Angeles (UCLA) shows that such higher-order brain centers, such as the prefrontal cortex, don't fully develop until young adulthood.  more

Diabetes linked to increased risk of Alzheimer's in long-term study
Diabetes mellitus was linked to a 65 percent increased risk of developing Alzheimer's disease (AD), appearing to affect some aspects of cognitive function differently than others in a new study supported by the National Institute on Aging (NIA) at the National Institutes of Health. The findings, from the Rush Alzheimer's Disease Center's Religious Orders Study, add to a developing body of research examining a possible link between diabetes and cognitive decline. The results reported today are among the first to examine how certain cognitive systems--memory for words and events, the speed of processing information, and the ability to recognize spatial patterns--may be affected selectively in people with diabetes. more

little clear gif used for a space